By combining the enzyme responsiveness of ET‐CORM with the tumor‐targeting specificity of trastuzumab, our platform achieves dual‐layer cancer selectivity, leveraging both HER2 overexpression and intracellular CatB activity for precise CO release. Here, TYRP1 is linked to cancer.